Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI)

BACKGROUND: The rising incidence of resistance to currently available antibiotics among pathogens, particularly Gram-negative pathogens, in complicated intra-abdominal infections (cIAIs) has become a challenge for clinicians. Ceftazidime/avibactam (CAZ-AVI) is a fixed-dose antibiotic approved in Eur...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Antimicrob Resist Infect Control
Main Authors: Kongnakorn, Thitima, Eckmann, Christian, Bassetti, Matteo, Tichy, Eszter, Di Virgilio, Roberto, Baillon-Plot, Nathalie, Charbonneau, Claudie
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6925481/
https://ncbi.nlm.nih.gov/pubmed/31890160
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13756-019-0652-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados